Below are the most recently updated broker updates which include ratings and price targets for China Biologic Products, Inc. (NASDAQ:CBPO).

03/01/2016 – Broker: Credit Suisse Rating: neutral downgrade

02/29/2016 – Broker: Jefferies Rating: buy New Target: 136 reiteration

01/07/2016 – Broker: Deutsche Bank Rating: buy New Target: 162 reiteration

07/09/2015 – Broker: Bank of America Merrill Lynch Rating: buy New Target: 135 newcoverage

01/26/2015 – Broker: Zacks Rating: outperform New Target: 82 upgrade

09/03/2014 – Broker: Aegis Capital Rating: buy New Target: 59 reiteration

The average price target from the most recent broker reports is 114.80

The stock decreased -0.45% (-0.54) during the last days session, reaching 119.03 and roughly 254251 shares were bought or sold by traders.

View other investors thoughts on China Biologic Products, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.